Article

System upgrades allow automated IOL delivery

Hardware and software upgrades for Alcon’s Infiniti Vision System include the Intrepid AutoSert IOL injector, which enables automated delivery of the IOL.

 

Fort Worth, TX-The latest hardware and software upgrades for Alcon’s Infiniti Vision System are expected to provide surgeons greater control during cataract surgery, including the Intrepid AutoSert IOL injector, which enables automated delivery of the IOL.

The IOL injector hardware features controlled, consistent IOL delivery, helping surgeons gain more precise surgical control during IOL insertion compared with the variable delivery forces that can be experienced using a manual injector.

The injector hardware and software upgrades also allow enhanced IOL insertion control, better globe stabilization, smoother insertions, support for all standard incision sizes, including micro-incision cataract surgery, and better wound integrity.

“We are pleased to offer our Infiniti Vision System customers the opportunity to expand the platform’s functionalities further. Intrepid AutoSert technology increases surgeons’ control during the IOL delivery step, further reducing another variable of the cataract procedure, and, in turn, continuing to maximize consistency in overall patient outcomes,” said Laurent Attias, head of global commercial strategy, Alcon.

The Infiniti Vision System hardware and software upgrade kit will become available globally during the first half of 2013.

For additional information concerning the IOL injector hardware or the Infiniti Vision System, visit www.infinitivision.com.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.